Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01288716 · ClinicalTrials.gov registry record · Phase 2
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
A Phase 2 study, sponsored by Seaside Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT01288716: Completed Phase 2 study, sponsored by Seaside Therapeutics.
NCT01288716 is a Phase 2 study that has completed, run by Seaside Therapeutics. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01288716, a Phase 2 study, has completed, sponsored by Seaside Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders
Interventions
- DRUG Arbaclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01288716
The ClinicalTrials.gov registry entry for NCT01288716 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seaside Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arbaclofen is the first listed.
NCT01288716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01288716 about?
NCT01288716 is a clinical study titled "Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders". To explore the efficacy, safety and tolerability of STX209 (arbaclofen) administered for the treatment of social withdrawal in subjects with autism spectrum disorders
What is the current status of trial NCT01288716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2011-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01288716?
The interventions under investigation include: Arbaclofen (DRUG).
Who is sponsoring clinical trial NCT01288716?
This trial is sponsored by Seaside Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.